Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ: BNTX )

97.47 -2.84 (-2.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
66 67 Next >
DraftKings Apologizes For 9/11 'Never Forget' Parlay Promotion, Apple Set For Selling 'Made In India' iPhone 15 on Launch Day, MGM Resorts Faces Ongoing Cyber Incident: Today's Top Stories
Benzinga 
Via Benzinga
Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits
The U.S. 
Via Benzinga
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
BioNTech Unusual Options Activity For August 30
Via Benzinga
Expert Ratings for BioNTech
Via Benzinga
BioNTech Unusual Options Activity For August 21
Via Benzinga
Non-Disappearing COVID Creates Another Chapter For The Pharmaceutical Industry
On Tuesday, UK regulators joined their US and European peers in approving an updated COVID-19 vaccine by Pfizer Inc (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) that targets only the... 
Via Benzinga
Exposures COVID-19
Here's How Moderna's Updated Covid Shot Stacks Up Against Highly Mutated 'Pirola' Variant
Pirola has about 30 mutations compared with previous omicron versions of the virus. 
Via Investor's Business Daily
Exposures COVID-19
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
Exposures COVID-19 Product Safety
Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle
Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'... 
Via Benzinga
Exposures COVID-19
What's Going On With BioNTech (BNTX) Stock?
BioNTech SE - ADR (NASDAQ:BNTX) shares are trading higher by 4.66% to $106.51 Wednesday morning as the stock continues to rebound after falling on Monday. 
Via Benzinga
Week In Review: GenFleet Out-Licenses Three Candidates To Verastem In $625 Million Deal
Shanghai GenFleet Technologies partnered three preclinical small-molecule candidates for RAS pathway-driven cancers to Verastem Oncology in a deal that could be worth up to $625.5 million. GenFleet... 
Via Talk Markets
Jeff Bezos Vs. Elon Musk Space Contract Lawsuit, Novo Nordisk's Famed Drug Ozempic Could Be Next Contender For Medicare Negotiations, Tesla Rival XPeng's August Deliveries Zooms 43%: Today's Top Stories
Tech Crunch 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Europe Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination Campaigns
The European Commission has approved Comirnaty XBB.1.5-adapted COVID-19 vaccine, developed by BioNTech SE (NASDAQ: 
Via Benzinga
Exposures COVID-19
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
Why Novavax Stock Was So Healthy on Monday
As the coronavirus threat rises, so too does the vaccine maker's value to investors. 
Via The Motley Fool
Exposures COVID-19
Why BioNTech Shares Are Rising During Monday's Session
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by some 2.25% to $120.26 Monday. The stock is gaining today amid rising COVID-19 cases in the U.S. 
Via Benzinga
Exposures COVID-19
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
COVID Is Making a Comeback: Should You Buy These 2 Stocks?
Can these companies keep up their recent momentum? 
Via The Motley Fool
Exposures COVID-19
Novavax (NVAX) Stock Is Getting Ready to Rally Again
Novavax only has an Emergency Use Authorization and faces a struggle to get paid for its protein-based Covid shot. 
Via InvestorPlace
Exposures COVID-19
Why Moderna, BioNTech SE, and Novavax Surged Today
The companies have developed vaccines for the current dominant strain of COVID, and the Biden administration is getting behind a new booster campaign. 
Via The Motley Fool
Exposures COVID-19
Moderna, BioNTech And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Dow Jones falling around 150 points on Monday. Here are some big stocks recording gains in today’s session. Genelux Corporation (NASDAQ: GNLX) gained 19.2% to $28.58.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Covid Vaccine Rally Dashed As Pfizer, Moderna Give Back Gains On Eris' Advance
The companies are hoping to launch their updated Covid shots in September. 
Via Investor's Business Daily
Exposures COVID-19
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies
Moderna Inc (NASDAQ: MRNA) announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies... 
Via Benzinga
Exposures COVID-19
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
From BioNTech SE
Via GlobeNewswire
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.